Stocks · News reference
Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose Cohort
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Lowers Price Target to $6
HC Wainwright & Co. analyst Yi Chen maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and lowers the price target from $7 to $6.
IP Australia Grants Patent To Anixa Biosciences’ Breast Cancer Vaccine Technology, Exclusively Licensed From Cleveland Clinic
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estateContinues expansion of global intellectual